Lactiplantibacillus plantarum Ln4 attenuates streptozotocin and high-fat diet-induced Type-2 diabetes

초록

Type-2 diabetes mellitus (T2DM) is an expanding global concern with limited efficacy of conventional therapies. Probiotics have gained attention for their ability to modulate gut microbiota and glucose homeostasis. This study evaluated the therapeutic potential of Lactiplantibacillus plantarum Ln4 at LOW (5 & times; 108 CFU/day) and HIGH (5 & times; 109 CFU/day) doses in an STZ/HFD-induced diabetic mouse model, compared with metformin (200 mg/kg). STZ/HFD induction resulted in reduced body and muscle weight, increased food and water intake, elevated fasting blood glucose, OGTT, AUC, HOMA-IR, liver weight, and dysregulated metabolic biomarkers. Ln4 administration significantly reversed these alterations, normalized serum adiponectin, insulin, GLP-1, and HbA1c levels, and improved lipid profile, oxidative stress markers, and histopathological changes in liver and skeletal muscle. Mechanistically, Ln4 restored GLUT-2, GLUT-4, GCK, IRS/PI3K/Akt, AMPK, and GSK3(3 signaling while suppressing PEPCK and PTP1B expression. Overall, L. plantarum Ln4 effectively ameliorated hyperglycemia and dyslipidemia, showing efficacy comparable to metformin.

키워드